2009 Influenza A H1N1 감염 중 소아 중증 환자에 대한 고용량 Oseltamivir 투여 효과
Effectiveness of double-dose oseltamivir for pediatric patients with severe 2009 pandemic influenza A H1N1
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: We aimed to evaluate the use and safety of double dose oseltamivir for patients manifesting severe respiratory symptoms or showing no improvement of clinical symptoms after 72 hours’ treatment with the usual oseltamivir dosage. Methods: We analyzed the clinical features of 2009 influenza A H1N1 inpatients who had been admitted to a university hospital’s Department of Pediatrics between August 2009 and January 2010. The Influenza A H1N1 diagnoses were confirmed by real-time reverse transcriptase polymerase chain reaction. Results: The study participants numbered 157 (mean age, 5.0 years; male-to-female ratio, 1.1:1). Among them, twenty (mean age, 5.2 years) were administered double dose oseltamivir. This double dose group showed higher peak body temperatures and more abnormal radiologic results than the other, usual-dose group. The mean time duration between high fever and afebrile status after initiation of double-dose oseltamivir administration was 2.1 days, whereas that within the usual-dose group was 1.7 days. There were no adverse effects in the patients treated with double-dose oseltamivir. Conclusion: Double-dose oseltamivir was well tolerated in patients with severe 2009 influenza A H1N1 infection.
Abstract
Purpose: We aimed to evaluate the use and safety of double dose oseltamivir for patients manifesting severe respiratory symptoms or showing no improvement of clinical symptoms after 72 hours’ treatment with the usual oseltamivir dosage. Methods: We analyzed the clinical features of 2009 influenza A H1N1 inpatients who had been admitted to a university hospital’s Department of Pediatrics between August 2009 and January 2010. The Influenza A H1N1 diagnoses were confirmed by real-time reverse transcriptase polymerase chain reaction. Results: The study participants numbered 157 (mean age, 5.0 years; male-to-female ratio, 1.1:1). Among them, twenty (mean age, 5.2 years) were administered double dose oseltamivir. This double dose group showed higher peak body temperatures and more abnormal radiologic results than the other, usual-dose group. The mean time duration between high fever and afebrile status after initiation of double-dose oseltamivir administration was 2.1 days, whereas that within the usual-dose group was 1.7 days. There were no adverse effects in the patients treated with double-dose oseltamivir. Conclusion: Double-dose oseltamivir was well tolerated in patients with severe 2009 influenza A H1N1 infection.
참고문헌 (22)
- Halasa NB, "Update on the 2009 pandemic influenza A H1N1 in children", Curr Opin Pediatr, 22, pp.83~87 (2010)
- Neuzil KM, "Burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study", J Infect Dis, 185, pp.147~152 (2002)
- "Clinical management of human infection with pandemic (H1N1) 2009: revised guidance" (2009)[URL]
- Hui DS, "Clinical management of pandemic 2009 influenza A(H1N1) infection", Chest, 137, pp.916~925 (2010)
- "Clinical management of adult patients with complications of pandemic influenza A(H1N1) 2009 influenza: emergency guidelines for the management of patients with severe respiratory distress and shock in district hospitals in limited-resource settings" (2010)[URL]
- ". Available from" (2010)[URL]
- To KK, "Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection", Clin Infect Dis, 50, pp.850~859 (2010)
- Bai L, "Clinical features of pneumonia caused by 2009 influenza A(H1N1) virus in Beijing, China", Chest, 139, pp.1156~1164 (2011)
- Okada T, "Characteristic findings of pediatric inpatients with pandemic (H1N1) 2009 virus infection among severe and nonsevere illnesses", J Infect Chemother, 17, pp.238~245 (2011)
- Hackett S, "Clinical characteristics of paediatric H1N1 admissions in Birmingham, UK", Lancet, 374, pp.605~ (2009)
- El-Radhi AS, "Thermometry in paediatric practice", Arch Dis Child, 91, pp.351~356 (2006)
- Binz P, "Different fever definitions and the rate of fever and neutropenia diagnosed in children with cancer: a retrospective two-center cohort study", Pediatr Blood Cancer, 60, pp.799~805 (2013)
- "Pocket guide for asthma management and prevention in children 5 years and younger" (2009)[URL]
- "Pocket guide for asthma management and prevention" (2012)[URL]
- Widmer N, "Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A", H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics, 2010, pp.49, 741~765
- Moscona A, "Neuraminidase inhibitors for influenza", N Engl J Med, 353, pp.1363~1373 (2005)
- Dutkowski R, "Safety and pharmacokinetics of oseltamivir at standard and high dosages", Int J Antimicrob Agents, 35, pp.461~467 (2010)
- Nicholson KG, "Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group", Lancet, 355, pp.1845~1850 (2000)
- Treanor JJ, "Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group", JAMA, 283, pp.1016~1024 (2000)
- Oo C, "Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children", Paediatr Drugs, 3, pp.229~236 (2001)
- Oo C, "Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1-5 years", Eur J Clin Pharmacol, 59, pp.411~415 (2003)
- Dutkowski R, "Safety and pharmacology of oseltamivir in clinical use", Drug Saf, 26, pp.787~801 (2003)